搜索结果
靶点ID:TCMBANKGE015165
靶点别名:AOF2; BHC110; CPRF; KDM1; LSD1
靶点描述:lysine demethylase 1A
染色体:1
染色体位置:1p36.12
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:29079
OMIM_Link:609132
Ensembl_Link:ENSG00000004487
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN012700 | coumestrol | NCIMech_000078; CCRIS 7311; A-Lactone; API0002121; Tox21_200032; MolPort-003-846-031; US8552057, 3; HMS3374A07; 3,9-Dihydroxy-6H-benzofuro[3,2-c]-[1]benzopyran-6-one; 6H-Benzofuro[3,2-c][1]benzopyran-6-one,3,9-dihydroxy-; Cumostrol; CHEBI:3908; C-16836; VZ31590; LS-35394; S00280; 3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one; MFCD00016885; SMP2_000163; DSSTox_RID_76572; 27885_FLUKA; 6H-Benzofuro[3, 3,9-dihydroxy-; 5-19-06-00405 (Beilstein Handbook Reference); BRN 0266702; 479-13-0; NSC22842; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone; C10205; 3,9-dihydroxy-[1]benzoxolo[3,2-c]chromen-6-one; AC1NQYXV; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone (6CI); NCGC00018124-01; DSSTox_CID_2399; CTK8F8799; Coumestrol, >=95.0% (HPLC); NCI60_001863; 4CN-2508; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; BIDD:ER0114; NCGC00018124-03; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one #; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; A1-00298; NSC 22842; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; CCG-35536; NCGC00018124-06; 3,9-bis(oxidanyl)-[1]benzofuro[3,2-c]chromen-6-one; ZINC1219; NCGC00257586-01; 3,9-Dihydroxy-benzo[4,5]furo[3,2-c]chromen-6-one; AIDS011954; SCHEMBL22012; UNII-V7NW98OB34; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; MLS000069446; CCG-36200; LMPK12090018; 3-Benzofurancarboxylic acid,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 7,12-Dihydroxycoumestan; CS-6343; D02DML; CHEMBL30707; 3,9-dihydroxy-6-benzofurano[3,2-c]chromenone; ZINC00001219; 5,14-dihydroxy-8,17-dioxatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2,4,6,11(16),12,14-heptaen-9-one; Oprea1_222511; MLS000738006; EINECS 207-525-6; 3,9-Dihydroxycoumestan; Coumestrol, BioReagent, suitable for fluorescence, >=97.5% (HPLC); A827386; DTXSID6022399; CAS-479-13-0; FT-0603177; ST50320052; 2-(2,4-Dihydroxyphenyl)-6-hydroxy-3-benzofurancarboxylic Acid ; 3,9-dihydroxybenzofurano[3,2-c]chromen-6-one; 3,9-dihydroxybenzo[d]chromeno[4,3-b]furan-6-one; NCGC00023462-03; AIDS-011954; V0359; Cumoestrol; DSSTox_GSID_22399; Cumoesterol; NCGC00018124-05; Coumestrol; NCGC00018124-04; V7NW98OB34; ZB000278; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; ST5320052; AN-6463; Cumestrol; NCGC00023462-04; NCGC00018124-02; CC-25990; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihdyroxy-; NSC-22842; 3,9-dihydroxybenzofuro[3,2-c]chromen-6-one; AKOS028111776; HMS2235B05; Coumesterol; COUMESTROL; BDBM23451; SMR000059001; HY-N2335; 27883_FLUKA | C15H8O5 | 268.22 | C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O |
| TCMBANKIN023145 | Coumurrayin | 5,7-dimethoxy-8-(3-methylbut-2-enyl)-2-chromenone; 5,7-dimethoxy-8-(3-methylbut-2-enyl)chromen-2-one; coumurrayin; 5,7-dimethoxy-8-(3-methylbut-2-enyl)coumarin; 17245-25-9 | C16H18O4 | 274.31 | CC(=CCC1=C(C=C(C2=C1OC(=O)C=C2)OC)OC)C |
| TCMBANKIN057906 | mercury | hydrargyrum | Hg | 200.59 g/mol | [Hg] |
| TCMBANKIN058306 | cinnamic acid | Cinnamic acid, (Z)-; trans-beta-Carboxystyrene; (Z)-3-phenylprop-2-enoate; Cinnamylic acid; trans-Zimtsaeure; Benzenepropenoic acid; Zimtsaeure; cinnamic acid ; 3-phenylprop-2-enoic acid; C80857_ALDRICH; 102-94-3; 133760_ALDRICH; AIDS-017619; tert-.beta.-Phenylacrylic acid; BRN 1905952; STK286093; InChI=1/C9H8O2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-7H,(H,10,11; CCRIS 3190; NSC174025; 3-Phenylpropenoic acid; CHEBI:35700; W228818_ALDRICH; cinnamicacid; (E)-3-Phenyl-2-propenoic acid; 4-09-00-02002 (Beilstein Handbook Reference); NSC623441; AC1OAGPW; 140-10-3; Benzylideneacetic acid; NSC44010; Zimtsaeure [German]; 2-Propenoic acid, 3-phenyl-, (E)-; 3-Phenyl-2-propenoic acid; NSC9189; 2-Propenoic acid, 3-phenyl-, (Z)-; trans-3-Phenylacrylic acid; C10438; W228826_ALDRICH; Cinnamic acid, (E)-; WLN: QV1U1R; NCGC00165979-01; NSC 44010; CHEBI:27386; (2Z)-3-phenylacrylate; trans-Cinnamic acid; (Z)-Cinnamic acid; (2E)-3-phenylprop-2-enoic acid; Acidum cinnamylicum; (2E)-3-phenyl-2-propenoic acid; 621-82-9; cis-.beta.-Carboxystyrene; PHENYLETHYLENECARBOXYLIC ACID; EINECS 210-708-3; 2-Propenoic acid, 3-phenyl-; 3-Phenylacrylic acid; CHEBI:35697; EINECS 205-398-1; cis-Cinnamic acid; BRN 0507757; C00423; (2Z)-3-phenylprop-2-enoate; Kyselina skoricove [Czech]; Phenylacrylic acid; Cinnamic acid; Cinnamic acid (natural); (E)-3-phenylacrylic acid; cis-cinnamate; AI3-00891; (2E)-3-phenylacrylic acid; Allocinnamic acid; (E)-3-phenylprop-2-enoic acid; (E)-Cinnamic acid; beta-phenylacrylic acid; AIDS017619; trans-Cinnamate; trans-.beta.-Carboxystyrene; trans-3-Phenyl-2-propenoic acid; 96340_FLUKA; FEMA No. 2288; trans-3-Phenylpropensaeure; NSC 9189; Isocinnamic acid; AI3-23709; cis-Cinnamic acidanion; E-cinnamicacid; E-cinnamic acid; E- cinnamicacid; 3-Phenylpropenoic acid | C9H8O2 | 148.16 | C1=CC=C(C=C1)C=CC(=O)O |
| TCMBANKIN058847 | Auraptene | 7-[(2E)-3,7-dimethylocta-2,6-dienoxy]-2-chromenone; NCGC00096070-03; NCGC00096070-04; NSC711511; 7-[(2E)-3,7-dimethylocta-2,6-dienoxy]coumarin; auraptene; MLS001049098; SPECTRUM1505176; STOCK1N-26363; SMR000386931; 7-Geranyloxycoumarin; 7-[(2E)-3,7-dimethylocta-2,6-dienoxy]chromen-2-one; ACon1_000071; ZINC01658901; MEGxp0_000091; auraptene ; 7-(3,7-dimethylocta-2,6-dienoxy)-2-chromenone; 2H-1-Benzopyran-2-one, 7-((3,7-dimethyl-2,6-octadienyl)oxy)-, (E)-; UPCMLD-DP061:001; 7-(3,7-dimethylocta-2,6-dienoxy)chromen-2-one; 7-(3,7-dimethylocta-2,6-dienoxy)coumarin; Coumarin, 7-[(3,7-dimethyl-2,6-octadienyl)oxy]-, (E)-; 2H-1-Benzopyran-2-one, 7-[(3,7-dimethyl-2,6-octadienyl)oxy]-, (E)-; 495-02-3; NCGC00096070-01; aurapten | C19H22O3 | 298.4 g/mol | CC(=CCCC(=CCOC1=CC2=C(C=C1)C=CC(=O)O2)C)C |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000061 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI001110 | Neoplasms | Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI002287 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | group | |
| TCMBANKDI002881 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI004500 | Neoplasms; Male Urogenital Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI006612 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI006652 | Nutritional and Metabolic Diseases; Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI006871 | Pathological Conditions, Signs and Symptoms | - | Pathologic Function | phenotype | |
| TCMBANKDI006900 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI007091 | Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI007141 | Neoplasms | - | Neoplastic Process; Experimental Model of Disease | disease | |
| TCMBANKDI007182 | Neoplasms; Hemic and Lymphatic Diseases | Abnormality of the immune system; Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | disease | |
| TCMBANKDI007618 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | phenotype | |
| TCMBANKDI007737 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI009821 | Pathological Conditions, Signs and Symptoms | - | Finding | phenotype | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI012424 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Pathologic Function | phenotype | |
| TCMBANKDI012976 | Neoplasms; Stomatognathic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI014805 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI015660 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI016364 | Neoplasms; Male Urogenital Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI016890 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017183 | - | Abnormality of the integument; Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI019056 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI020119 | Mental Disorders | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI023140 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI023464 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI024001 | - | - | Laboratory Procedure | phenotype | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024561 | - | - | Neoplastic Process | disease | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI027026 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI029861 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI030653 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI031192 | Neoplasms; Male Urogenital Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI031381 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI031570 | - | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease |
滇IICP备16009434号-1 |
Dai SX Lab